Cargando…

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer

BACKGROUND: SPRED1 and 2 are key negative regulators of MAPK signalling in mammalian cells. Here, we investigate the expression and functional role of SPREDs in prostate cancer. METHODS: A transcriptome bank of microdissected grade-specific primary cancers was constructed and interrogated for transc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kachroo, N, Valencia, T, Warren, A Y, Gnanapragasam, V J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593530/ https://www.ncbi.nlm.nih.gov/pubmed/23169297 http://dx.doi.org/10.1038/bjc.2012.507

Ejemplares similares

Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease
por: Darby, S, et al.
Publicado: (2009)

Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer
por: Kawano, Y, et al.
Publicado: (2009)

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients
por: Hagman, Z, et al.
Publicado: (2013)

The TGF-β signalling negative regulator PICK1 represses prostate cancer metastasis to bone
por: Dai, Yuhu, et al.
Publicado: (2017)

Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells
por: Hirata, H, et al.
Publicado: (2014)

Arpin downregulation in breast cancer is associated with poor prognosis
por: Lomakina, Maria E, et al.
Publicado: (2016)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells
por: Hirata, H, et al.
Publicado: (2013)

Lacking hypoxia-mediated downregulation of E-cadherin in cancers of the uterine cervix
por: Mayer, A, et al.
Publicado: (2013)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis
por: Otsubo, T, et al.
Publicado: (2008)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2010)

The prognostic significance of vasohibin-1 expression in patients with prostate cancer
por: Kosaka, T, et al.
Publicado: (2013)

Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma
por: Onda, T, et al.
Publicado: (2006)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer
por: Sasahira, T, et al.
Publicado: (2012)

microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity
por: Zhang, J, et al.
Publicado: (2010)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer
por: Ahmad, I, et al.
Publicado: (2013)

MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis
por: Wu, W, et al.
Publicado: (2013)

Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress
por: Whitaker, H C, et al.
Publicado: (2013)

Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game
por: Basanta, D, et al.
Publicado: (2012)

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
por: Attard, G, et al.
Publicado: (2008)

microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
por: Ueno, K, et al.
Publicado: (2013)

HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation
por: Jung, C, et al.
Publicado: (2005)

Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer
por: Baron, V T, et al.
Publicado: (2015)

Disabled-2 downregulation promotes epithelial-to-mesenchymal transition
por: Martin, J C, et al.
Publicado: (2010)

Circulating cell-free miRNAs as biomarker for triple-negative breast cancer
por: Shin, V Y, et al.
Publicado: (2015)

Downregulation of miRNA-424: a sign of field cancerisation in clinically normal tongue adjacent to squamous cell carcinoma
por: Boldrup, L, et al.
Publicado: (2015)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma
por: Mizukami, Y, et al.
Publicado: (2008)

Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence
por: Truong, M, et al.
Publicado: (2012)

Loss of Coxsackie and adenovirus receptor downregulates α-catenin expression
por: Stecker, K, et al.
Publicado: (2009)

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement
por: Foster, C S, et al.
Publicado: (2009)

Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer
por: Koike, H, et al.
Publicado: (2005)

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors
por: Xu, Y, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_igjdgn3g1cnqi0uoepoeaech55